Scancell Holdings plc (LON:SCLP – Get Free Report)’s share price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 13.76 ($0.17) and traded as low as GBX 9.50 ($0.12). Scancell shares last traded at GBX 10.10 ($0.12), with a volume of 844,442 shares traded.
Scancell Price Performance
The firm has a 50 day moving average of GBX 12.30 and a two-hundred day moving average of GBX 13.76. The company has a market cap of £93.89 million, a PE ratio of -1,010.00 and a beta of 0.35. The company has a current ratio of 3.42, a quick ratio of 13.01 and a debt-to-equity ratio of 61.41.
Scancell Company Profile
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer.
Recommended Stories
- Five stocks we like better than Scancell
- How to Use the MarketBeat Dividend Calculator
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Energy and Oil Stocks Explained
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Pros And Cons Of Monthly Dividend Stocks
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
